Amarantus BioSciences Announces Completion of Capital Restructuring
June 14 2011 - 11:06AM
Marketwired
Amarantus BioSciences, Inc. (OTCBB: AMBS), a California-based
biotechnology company developing first-in-class proteins, today
announced the successful completion of the Company's capital
restructuring initiatives, including a 25-for-1 forward stock split
(the "Forward Stock Split"), which was previously approved by its
stockholders and announced on June 2, 2011. According to FINRA's
confirmation, the Forward Stock Split became effective on June 13,
2011 (the "Effective Date"). As of the Effective Date, and as a
result of the Forward Stock Split, there are approximately
67,000,000 shares issued and outstanding.
"By effecting the previously-announced forward stock split,
Amarantus has created a more attractive capital structure, thereby
enhancing our visibility in the public equity markets," said Martin
D. Cleary, Amarantus' Chairman and CEO. "Furthermore, today's
announcement demonstrates our continued emphasis on aligning
shareholders' interests with the solid execution of our business
plan."
Amarantus' lead product candidate, MANF, is a first-in-class,
naturally-occurring therapeutic protein that has broad applications
in the treatment of devastating human diseases related to protein
misfolding and apoptosis, such as diabetes, cardiac ischemia and
neurodegenerative diseases. With a combined market opportunity of
$350 billion, the Company is focused on executing successful
pre-clinical programs in these indications for which there remains
a significant unmet medical need.
About Amarantus BioSciences, Inc.
Amarantus BioSciences, Inc. is engaged in the research and
development of first-in-class disease-modifying treatments that
address the underlying cause of cell death, known as apoptosis,
associated with a wide range of diseases. The Company's most
advanced product candidate, MANF, is a therapeutic protein
indicated for the treatment of Parkinson's disease and Myocardial
Infarction. Currently incubating at the Parkinson's Institute in
Sunnyvale, CA, Amarantus BioSciences is the recipient of a research
grant from The Michael J. Fox Foundation for Parkinson's Research.
See www.amarantus.com.
Forward Looking Safe-Harbor Statement:
The information provided herein may include forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, and Section 21E of the Exchange Act of 1934. These
forward-looking statements are largely based on our current
expectations and projections about future events and financial
trends affecting the financial condition of our business. Such
forward-looking statements include, in particular, statements about
our plans, strategies, business prospects, and the ongoing and
future development of disease modifying treatments. These
forward-looking statements may be identified by the use of terms
and phrases such as "anticipates," "believes," "can," "could,"
"estimates," "expects," "forecasts," "intends," "may," "plans,"
"projects," "targets," "will," and similar expressions or
variations of these terms and similar phrases. Additionally,
statements concerning future matters such as planned research and
development and the regulatory approval, marketing, and sale of
planned future and other statements regarding matters that are not
historical are forward-looking statements. Management cautions that
these forward-looking statements relate to future events or our
future financial performance and are subject to business, economic,
and other risks and uncertainties, both known and unknown, that may
cause actual results, levels of activity, performance or
achievements of our business or our industry to be materially
different from those expressed or implied by any forward-looking
statements.
These forward-looking statements involve risks and uncertainties
that could cause actual results to differ materially from those
projected, including without limitation, the following: (a) the
risk that our product candidate MANF, which is still under clinical
development, may not obtain regulatory approval or be successfully
commercialized; (b) the risk that extensive regulatory requirements
may limit the scope of future sales or impede successful product
commercialization even if we obtain regulatory approval for our
product candidate; (c) the risk that we may be unable to arrange
for the successful manufacture and commercial supply of our planned
product; (d) the risk that MANF, if approved and brought to market,
may not be accepted by the medical community; (e) the risk that we
may not be successful in undertaking the steps currently planned in
order to increase our liquidity and capital resources, resulting in
inadequate funding for our planned research and development
activities; and (f) other risks and uncertainties described in our
filings with the Securities and Exchange Commission.
Neither management nor any other person assumes responsibility
for the accuracy and completeness of the forward-looking
statements. All forward-looking statements in this press release
are made as of the date hereof, based on information available to
us as of the date hereof, and subsequent facts or circumstances may
contradict, obviate, undermine, or otherwise fail to support or
substantiate such statements. We caution you not to rely on these
statements without also considering the risks and uncertainties
associated with these statements and our business that are
addressed in our filings with the Securities and Exchange
Commission that are available on the SEC's web site located at
www.sec.gov. Certain information included in this press release may
supersede or supplement forward-looking statements in our other
Exchange Act reports filed with the SEC. We assume no obligation to
update any forward-looking statement to conform such statements to
actual results or to changes in our expectations, except as
required by applicable law or regulation.
CONTACTS: Susan Kim 212-203-4433 pr@amarantus.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From May 2024 to Jun 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Jun 2023 to Jun 2024